Erica Lyndrup Herzog MD, PhD

Associate Professor of Medicine (Pulmonary); Director, Translational Lung Research Program; Co-Director, Yale Fibrosis Program; Assistant Director, Medical Student Research, Department of Medicine; Director, Interstitial Lung Disease Center of Excellence

Clinical Interests

Interstitial lung disease, idiopathic pulmonary fibrosis, scleroderma, sarcoidosis, diffuse parenchymal lung disease

Board Certifications

Critical Care Medicine (Internal Medicine), Board Certified

Patient Care Locations


Clinical Trials

ConditionsStudy Title
Alpha 1 Antitrypsin Deficiency and AATD(GRADS)(A) - Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis
Sarcoidosis(GRADS)(B) - Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidsosis
Idiopathic Pulmonary Fibrosis(RAINIER) A Phase 2, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Assess the Efficacy and safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (GS-US-322-027)
Pulmonary Fibrosis(BMS-IM136003) Clinical protocol IM136003 and efficacy of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis, a multicenter, randomized, double-blind, placebo-controlled phase 2 study of the safety and efficacy of BMS-986020 in subjects with IPF
Idiopathic Pulmonary Fibrosis(GB28547) A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Idiopathic Pulmonary Fibrosis

More Clinical Trials...

Edit Profile